Advancing Buntanetap: Comparative Pharmacokinetic Characterization of the Original Semi‐Crystalline with the Novel Crystalline Form in Animals and Humans

These findings support the continued development of Form B for future clinical use, as it combines enhanced solid-state stability with a preserved PK profile essential for buntanetap's therapeutic efficacy. Form B has also been approved by the FDA for all future clinical studies including the ongoing pivotal Phase 3 Early AD trial.